Certara Executive and Leadership Team

Jon Resnick, the Chief Executive Officer at Certara, directs the overarching corporate strategy and long-term vision for the organization. Resnick oversees the integration of biosimulation technologies into the global drug development lifecycle, ensuring that scientific consulting services align with the evolving needs of pharmaceutical partners. By managing high-level relationships with the Board and executive leadership, the Chief Executive Officer drives operational excellence across all business units. This leadership role involves scaling the company's AI-driven platforms to improve clinical trial efficiency and regulatory submission success. Jon Resnick maintains a focus on market expansion and the delivery of value to stakeholders through innovation. Ultimately, Resnick secures the company's position as a leader in model-informed drug development by fostering a culture of scientific rigor and technological advancement across the entire enterprise.

Faiz Mohammed, the Interim Chief Financial Officer. at Certara, directs the financial planning, reporting, and capital allocation strategies for the organization. Mohammed oversees the fiscal health of the company, ensuring that resources support the growth of AI-driven platforms and scientific consulting services. By managing financial risk and investor relations, the Interim Chief Financial Officer. ensures alignment with the company's long-term strategic goals in the drug development sector. This leadership role involves optimizing operational budgets to support global expansion and the acquisition of new technologies. Faiz Mohammed drives financial transparency and accountability across all departments, providing the necessary data to support executive decision-making. Through rigorous financial oversight, Mohammed secures the stability required to invest in the next generation of biosimulation tools, ultimately supporting the company's mission to improve clinical outcomes for patients worldwide.

Adrian McKemey, the President, Certara Drug Development Solutions at Certara, directs the delivery of scientific consulting services across the entire drug development lifecycle. McKemey oversees the operational teams that provide expertise in preclinical modeling, clinical trials, and regulatory submissions. By integrating biosimulation into client workflows, the President, Certara Drug Development Solutions ensures that pharmaceutical partners achieve optimal clinical outcomes. This leadership role involves managing client relationships and ensuring the high-quality execution of complex development projects. Adrian McKemey drives the expansion of consulting capabilities to meet the needs of global markets, focusing on efficiency and scientific accuracy. Through the application of model-informed drug development, McKemey supports the company's goal of accelerating the delivery of new therapies to patients. Ultimately, McKemey ensures that the consulting division remains a cornerstone of the company's value proposition.

Martin Snyder, the President, Certara Data Sciences at Certara, directs the advanced data analytics and computational research initiatives that underpin the company's software platforms. Snyder oversees the data science teams responsible for developing algorithms that predict drug behavior and optimize clinical trial design. By leveraging large-scale datasets, the President, Certara Data Sciences ensures that the company's technology remains at the forefront of the industry. This leadership role involves collaborating with the technology and consulting divisions to translate complex data into actionable insights for pharmaceutical clients. Martin Snyder drives the development of new analytical tools that enhance the accuracy of biosimulation models. Through the application of rigorous data science, Snyder supports the company's mission to improve the efficiency of the drug development lifecycle, ultimately contributing to faster and more reliable regulatory submissions for global partners.

Leif Pedersen, the President & Chief Commercial Officer at Certara, directs the global sales, business development, and commercial strategy for the company's software and services. Pedersen oversees the commercial teams responsible for expanding the company's footprint in the pharmaceutical and biotechnology sectors. By managing the sales pipeline and client acquisition strategies, the President & Chief Commercial Officer ensures that the company's biosimulation platforms are adopted across the drug development lifecycle. This leadership role involves identifying new market opportunities and fostering long-term partnerships with global organizations. Leif Pedersen drives revenue growth by aligning commercial efforts with the specific needs of clients in clinical trials and regulatory affairs. Through strategic market penetration and customer success initiatives, Pedersen secures the company's position as a market leader, ensuring that the organization continues to deliver significant value to its diverse client base.

Sheila Rocchio, the Chief Marketing Officer at Certara, architects the global brand strategy and market positioning for the company's software and consulting services. Rocchio oversees the communication of complex biosimulation value propositions to pharmaceutical and biotechnology clients worldwide. By aligning marketing initiatives with the drug development lifecycle, the Chief Marketing Officer ensures that the company's AI-driven platforms reach key decision-makers in the R&D sector. This leadership role involves managing demand generation, product marketing, and corporate communications to support revenue growth. Sheila Rocchio drives engagement through targeted campaigns that highlight the impact of model-informed drug development on clinical outcomes. Through strategic market analysis and brand development, Rocchio strengthens the company's presence in competitive international markets, ensuring that the organization remains the preferred partner for innovative drug development solutions.

Chris Bouton, the Chief Technology Officer at Certara, directs the development and deployment of the company's proprietary software and AI-driven platforms. Bouton oversees the engineering teams responsible for building scalable biosimulation tools that predict drug behavior throughout the development lifecycle. By collaborating with scientific consultants, the Chief Technology Officer ensures that technical solutions meet the rigorous demands of regulatory submissions and clinical trials. This leadership role involves managing the product roadmap and integrating advanced data science capabilities into the existing software suite. Chris Bouton drives technological innovation to maintain the company's competitive edge in the life sciences industry. Through the continuous improvement of computational models, Bouton enables clients to optimize drug discovery and preclinical modeling, ultimately reducing the time and cost associated with bringing new therapies to market.

Rona Anhalt, the Chief Human Resources Officer at Certara, directs the talent acquisition, organizational development, and employee engagement strategies for the company. Anhalt oversees the recruitment of top-tier scientific and technical talent necessary to maintain the company's leadership in biosimulation and drug development. By fostering a culture of innovation and collaboration, the Chief Human Resources Officer ensures that the workforce remains aligned with the company's mission to optimize clinical outcomes. This leadership role involves managing performance management systems, compensation structures, and professional development programs that support a global team. Rona Anhalt drives initiatives that promote diversity and inclusion, ensuring that the organization attracts the best minds in the industry. Through strategic human capital management, Anhalt supports the operational scale required to deliver high-quality consulting services and software solutions to pharmaceutical clients across the globe.